Hayward, California – December 9, 2013 – Advanced Cell Diagnostics, Inc. (ACD), a world leader in the field of in situ nucleic acid detection for life science research and clinical diagnostics, is pleased to announce today the appointment of Joseph Keegan as a director to the company's board. In this position, Dr. Keegan will apply his extensive and successful business experience in the life science industry to help accelerate ACD's growth and expand its international presence.
Dr. Keegan brings more than 30 years of experience managing high growth life science businesses. Dr. Keegan served as the CEO of ForteBio since September of 2007 and he built the company from a startup into a fast growing leader in label-free analysis. Under his leadership, the company generated compounded annual revenue growth of 45% to $27M. It was acquired in 2012 by Pall Corporation, returning $160M to investors. Previously, Dr. Keegan was the CEO of Molecular Devices (MDC). During his 9-year tenure at MDC, Dr. Keegan grew the company’s revenue from $30M to $185M and he sold the company to MDS for $615M in 2007. Prior to MDC, Dr. Keegan served as President of Worldwide Tissue Culture of Becton Dickinson and Vice President of Microscope and Scientific Instruments Division of Leica.
"It is a great pleasure to welcome Dr. Keegan to our board when the company is experiencing rapid growth." said Dr. Yuling Luo, President and CEO of ACD. "Joe's remarkable success in building both ForteBio and Molecular Devices, and his extensive experience in both research and diagnostic industries make him an ideal addition to the board."
"RNAscope technology developed by ACD is a breakthrough in situ nucleic acid detection platform with wide-ranging market opportunities in both life science research and clinical diagnostics," said Dr. Keegan. "I am very pleased to join the ACD board and look forward to helping the company in its rapid growth and expansion."
About Advanced Cell Diagnostics, Inc.
Advanced Cell Diagnostics, Inc. is a leader in the emerging field of molecular pathology, developing cell and tissue-based research tools for all areas of biomedical research, and diagnostic tests for personalized medicine. The company’s products and services are based on its proprietary RNAscope® technology, the most sensitive method available for RNA in situ hybridization, and the first quantitative and fully automated platform enabling multiplex fluorescent and chromogenic RNA biomarker analysis. ACD partners with pharmaceutical and biotechnology companies to validate biomarkers for targeted therapeutic development in cancer and other diseases. These partnerships provide the foundation for ACD to develop companion diagnostic tests in conjunction with partners’ targeted therapeutics. ACD also pursues internal programs to develop proprietary diagnostic tests in cancer management. Learn more about ACD and RNAscope® technology at www.acdbio.com.
Steve Chen, Ph.D.
Chief Operating Officer